ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rocbrutinib

Also written as “Rocbrutinib”, “LP-168 tablet” and “LP-168”.

Its studies are mostly in Lymphoma, Mantle-Cell · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Sclerosis, Relapsing-Remitting · Waldenstrom Macroglobulinemia, led by 2 companies.

Drug pageRocbrutinib: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 13, 202615 company-led studies, 12 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lupeng Pharmaceutical1411 open or runningphase 3since Jan 13, 2026Feb 22, 2021Mar 31, 2027phase 1 · NCT04993690
Hansoh Pharmaceutical Groupits history only11 open or runningphase 2since Mar 4, 2025Mar 4, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lupeng Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 22, 2021First study: phase 1 study in Waldenstrom MacroglobulinemiaFirst studyNCT04775745 · 60 planned · United States
  2. Jul 27, 2021Phase 1 study in Lymphoma, B-CellNCT04993690 · 200 planned · China
  3. Jun 14, 2022Phase 1 study in Multiple SclerosisNCT05432713 · 70 enrolled · China
  4. Jan 19, 2023Phase 2 study in Lymphoma, Mantle-CellNCT05716087 · 62 enrolled · China
  5. Jun 15, 2023Phase 1 study in Lymphoma, Mantle-CellNCT05917964 · 22 enrolled · China
  6. Aug 6, 2023Named rocbrutinibINNProposed as its International Nonproprietary Name in WHO's List 129 · before, LP-168
  7. Nov 7, 2023Phase 1 study in Clinical PharmacologyNCT06126861 · 6 enrolled · China
  8. Feb 1, 2024Phase 1 study in Lymphoma, B-CellNCT06251180 · 112 enrolled · China
  9. Sep 16, 2025Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07189065 · 150 planned · China
  10. Jan 13, 20262 phase 3 studiesPhase 3 reachedNCT07377578, NCT07342478
  11. Jan 16, 2026Phase 1 study in Clinical PharmacologyNCT07374224 · 28 planned · China
  12. Apr 22, 2026Phase 1 study in DLBCLNCT07570017 · 42 planned · China
  13. May 20, 2026Phase 2 study in Lymphoma, Mantle-CellNCT07609862 · 92 planned · China
  14. Aug 7, 2026Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT07776743 · 30 planned · China

Ahead

  1. Mar 31, 2027Primary completion: phase 1 study in Lymphoma, B-CellNCT04993690
  2. Jun 30, 2027Primary completion: phase 1 study in Lymphoma, B-CellNCT06251180
  3. Dec 31, 2027Primary completion: phase 1 study in DLBCLNCT07570017
  4. Dec 31, 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07189065

TargetBeta

BTK →read by rule
“An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 14 Lupeng Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07776743Multiple Sclerosis, Relapsing-Remitting · China2RecruitingJun 202830
NCT07609862Lymphoma, Mantle-Cell · China2RecruitingJun 30, 202992
NCT07570017DLBCL · China1RecruitingDec 31, 202742
NCT07374224Clinical Pharmacology · China1RecruitingJun 30, 202628
NCT07377578Lymphoma, Mantle-Cell · China3RecruitingMay 30, 2031394
NCT07342478Leukemia, B-Cell · United States, France3RecruitingOct 30, 2029306
NCT07189065Lymphoma, Large B-Cell, Diffuse · China2RecruitingDec 31, 2027150
NCT06251180Lymphoma, B-Cell · China1Active, not recruitingJun 30, 2027112
NCT06126861Clinical Pharmacology · China1CompletedFeb 2, 20246
NCT05917964Lymphoma, Mantle-Cell · China1CompletedAug 21, 202322
NCT05716087Lymphoma, Mantle-Cell · China2Active, not recruitingDec 5, 202462
NCT05432713Multiple Sclerosis · China1CompletedNov 20, 202270
NCT04993690Lymphoma, B-Cell · China1RecruitingMar 31, 2027200
NCT04775745Waldenstrom Macroglobulinemia · United States1RecruitingDec 31, 202760

How it is read

Names in the registry

  • “Rocbrutinib”, 7 entries
  • “LP-168 tablet”, 3 entries
  • “LP-168”, 2 entries
  • “Lacutoclax+Rocbrutinib”, 1 entry
  • “Rocbrutinib tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.